Table 1 Summary of study characteristics and costs per DALY averted for interventions targeting all ages
References | Publication year | Country/region | Malaria intervention | Main data sources | Life tables source | Cost-effectiveness threshold used | Cost-effectiveness ratio (cost per DALY averted in US $) | DALYs averted per $ 1 million spent on intervention |
|---|---|---|---|---|---|---|---|---|
[1] | 1999 | Brazil | Case treatment, vector control and insecticide spraying | Malaria control program | GBD study | Not stated | $69 | 14,493 |
[2] | 1999 | Model | ITNs | Model Assumptions | GBD study | US$ 30 and US$ 150 | <$150 | <6667 |
[3] | 2001 | Zambia | Environmental management, treatment and mosquito nets | Malaria control program data | West African model life table | Not stated | $524–591 over a period of 3–5 years | 1799 |
[4] | 2002 | Zambia | Integrated malaria control (environmental management, rapid diagnosis and treatment and the use of bed nets | Census Hospital patient records | West African model life table | Not stated | $36.90 (average) | 27,100 |
[5] | 2005 | Multi-country | Combination of strategies | Reports WHO databases Expert opinion Published data | WHO life tables | Not stated | $10–100 | 18,182 |
[6] | 2006 | Kenya | Malaria home management Educational programme | Census Published data Surveys | Model | US$ 30 and US$ 150 | <$30 | <33,333 |
[7] | 2006 | Non-specific | Case management | Simulation model | Ethiopian life table | Not stated | Not specified | Â |
[8] | 2008 | Sub-Saharan | Diagnostic methods | Published and unpublished data Expert opinion | West African life table | US$ 150 | >US$ 70 (95% certainty and $40% malaria prevalence) | >14,286 |
[9] | 2008 | Multi-country | IRS ITNs | Published data ITN and IRS programmes | Not specified | US$ 30 and US$ 150 | $56 (calculated average) | 17,857 |
[10] | 2009 | Kenya and Uganda | Early detection system | Health facilities | Â | US$ 30 and US$ 150 | <$150 | <6667 |
[11] | 2009 | Non-specific | Vaccines (PEV, BSV, MSTBV and combinations) | Published data WHO estimates | Ethiopian life table | Not stated | $31 (pre-erythrocytic vaccine at $2 dose) | 32,258 |
$13.50 (blood stage vaccine at $2 dose) | 74,074 | |||||||
[12] | 2009 | Eritrea | ITNs | Published data National malaria control programme | WHO | US$ 30 and US$ 150 | $13–44 | 34,483 |
[13] | 2010 | Model | Pre-referral rectal antimalarial treatment | Published data World malaria report | Region-specific | US$ 30 and US$ 150 | $5 (in SSA) | 200,000 |
[14] | 2011 | Model | Pre-erythrocytic malaria Vaccine | Â | Ethiopian life table | US$ 30 and US$ 150 | I$207 (ceiling ratio) | 4831 |
[15] | 2012 | Kenya | LLINs | Published data Epidemiologic data | Â | Not stated | <$20 | <50,000 |
[16] | 2013 | Experimental Model | LLINs | Published studies | Country specific | US$ 30 and US$ 150 | US$ 235.28 | 4250 |
[17] | 2013 | Model | LLINs | Simulation | Country specific | US$ 30 and US$ 150 | US$ 235.28 | 4250 |
[18] | 2013 | Multi-country | Pre-erythrocytic Vaccine | UN population division WHO | WHO | 1–3 times GDP per capita | $56 | 17,857 |
[19] | 2014 | Tanzania | Larviciding | Malaria control program | GBD 2010 | 1-3 times GDP per capita | $ 43-$ 545 (depending on scenario) | 3401 |
[20] | 2014 | Kenya | Combined interventions (IRS, LLINs, AL | Published data Survey | Ethiopian life table | Not stated | $4.29–$55.70 (depending on the intervention) | 33,339 |
[21] | 2015 | Multi-country | Dihydroartemisinin–piperaquine (DP) Artemether–lumefantrine (AL) | Multi-centre clinical trial | WHO life table | Not stated | $ 5 (for DP) | 200,000 |
[22] | 2015 | Myanmar | RDTs | Published data Management information system | World Bank Global burden of study (2012) | Not stated | $639a | 1565 |
[23] | 2015 | China | Malaria elimination | Published data Infectious disease information system | Chinese life table | Not stated | Not specified | Not applicable |
[24] | 2016 | Model | RTS,S/AS01 malaria vaccine | Â | Ethiopian life table | Not stated | $ 80 (3 dose schedule at $5 per dose) | 12,500 |